Cholangiocarcinoma Non-resectable: Clinical Trials

20 trials for Cholangiocarcinoma Non-resectable, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 recruiting, 4 completed, 3 terminated, 3 unknown. 9 Phase 2, 5 Not applicable, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 3, Recruiting 3, Unknown 2, Active not recruiting 1
Not applicable5Recruiting 3, Completed 1, Terminated 1
Phase 12Terminated 2
Phase 31Enrolling by invitation 1

Follow Cholangiocarcinoma Non-resectable: new trials by email Literature Review of Cholangiocarcinoma Non-resectable trials Research Report on Cholangiocarcinoma Non-resectable

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
Preoperative Right Hepatic Artery Embolization - Cholangiocarcinoma Non-resectable
Not applicableRecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University332026-04-012026-11-09
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
Not yet recruitingAarhus University Hospital3002026-03-152026-03-06
CT-95 in Advanced Cancers Associated With Mesothelin Expression
CT-95 - Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
Phase 1TerminatedContext Therapeutics Inc.192025-03-312026-11-05
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
Liver transplantation after en bloc resection of the liver and pancreas - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent
Not applicableRecruitingOslo University Hospital152025-01-012025-08-21
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
HAIC, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable
Phase 2RecruitingTongji Hospital362024-06-042026-07-22
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma
Phase 2RecruitingBeth Israel Deaconess Medical Center302024-02-132026-04-22
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
DEB-TACE, Lenvatinib plus pucotenlimab - Cholangiocarcinoma Non-resectable
Phase 2UnknownTongji Hospital362023-12-092024-01-09
A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Ivosidenib - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Phase 2Active not recruitingServier122023-10-102025-12-09
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction
Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer
Phase 3Enrolling by invitationErasmus Medical Center1482023-08-092024-11-04
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
Candonilimab, Cisplatin, Gemcitabine - Cholangiocarcinoma Non-resectable
Phase 2UnknownWest China Hospital652023-07-012023-08-07
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1 - Cholangiocarcinoma Non-resectable
UnknownZe-yang Ding, MD1002022-02-012024-01-09
Photodynamic Therapy for Cholangiocarcinoma
Hematoporphyrin - Cholangiocarcinoma Non-resectable
Not applicableCompletedHepatopancreatobiliary Surgery Institute of Gansu Province862021-04-172024-11-20
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
TACE with ICI - Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
Not applicableRecruitingTianjin Medical University Cancer Institute and Hospital402020-10-272024-07-05
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
Gemcitabine-Oxaliplatin Regimen, Hepatic intra arterial chemotherapy - Cholangiocarcinoma Non-resectable, Non-metastatic
Phase 2RecruitingUniversity Hospital, Montpellier402018-06-112026-01-05
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma
Phase 2CompletedAIO-Studien-gGmbH1282018-05-022023-06-15
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC294640, Hydroxychloroquine Sulfate 200 MG - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
Phase 2CompletedRedHill Biopharma Limited652018-03-072025-07-23
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
nal-IRI, 5-FU, leucovorin - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic
Phase 2CompletedAIO-Studien-gGmbH1002017-10-242022-05-18
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic
Phase 1TerminatedHalozyme Therapeutics852017-10-022020-02-07
RFA RCT for Pancreatic or Bile Duct Cancer
Radiofrequency Ablation using EndoHPB Probe, Stenting only - Unresectable Pancreatic Cancer, Cholangiocarcinoma Non-resectable
Not applicableTerminatedWeill Medical College of Cornell University82014-06-012019-09-30
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
ABC294640 - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
No longer availableRedHill Biopharma Limited2025-03-18

Narrower conditions

Cholangiocarcinoma (12)  ·  Klatskin Tumor (5)  ·  Gallbladder Neoplasms (3)  ·  Neoplasms (2)  ·  Bile Duct Neoplasms (1)  ·  Biliary Tract Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Colorectal Neoplasms (1)  ·  Mesothelioma, Malignant (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasm, Residual (1)  ·  Pancreatic Neoplasms (1)

Broader conditions

Carcinoma (15)  ·  Neoplasms by Histologic Type (15)  ·  Neoplasms, Glandular and Epithelial (15)  ·  Adenocarcinoma (14)  ·  Neoplasms (14)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Biliary Tract Diseases (4)  ·  Biliary Tract Neoplasms (3)  ·  Gallbladder Diseases (3)  ·  Cholangiocarcinoma (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Neoplastic Processes (2)

Interventions

Cisplatin (3)  ·  Gemcitabine (3)  ·  3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (2)  ·  durvalumab (2)  ·  lenvatinib (2)  ·  Fluorouracil (1)  ·  Hematoporphyrins (1)  ·  Hydroxychloroquine (1)  ·  Leucovorin (1)  ·  PEGPH20 (1)  ·  Pancreatic Hormones (1)  ·  Yttrium-90 (1)  ·  atezolizumab (1)  ·  gemcitabine-oxaliplatin regimen (1)  ·  irinotecan sucrosofate (1)

Sponsors

AIO-Studien-gGmbH (2)  ·  RedHill Biopharma Limited (2)  ·  Tongji Hospital (2)  ·  Aarhus University Hospital (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Context Therapeutics Inc. (1)  ·  Erasmus Medical Center (1)  ·  Halozyme Therapeutics (1)  ·  Hepatopancreatobiliary Surgery Institute of Gansu Province (1)  ·  Oslo University Hospital (1)  ·  Servier (1)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)  ·  University Hospital, Montpellier (1)  ·  Weill Medical College of Cornell University (1)

Countries

China (7)  ·  United States (5)  ·  Germany (2)  ·  Denmark (1)  ·  France (1)  ·  Japan (1)  ·  Netherlands (1)  ·  Norway (1)  ·  South Korea (1)  ·  Thailand (1)

Top investigators

Ze-yang Ding, M.D. (2)  ·  Andrea Bullock, MD, MPH (1)  ·  Arndt Vogel, Prof. (1)  ·  Arndt Vogel, Prof. Dr. (1)  ·  Karen Chagin, MD (1)  ·  Karen-Lise Garm Spindler, Professor, MD, PhD (1)  ·  Lise Thorsen, Associate professor, MD, PhD (1)  ·  Mitesh Borad, MD (1)  ·  Mohamed Metwally, Consultant, MD, PhD (1)  ·  Reem Z Sharaiha, MD (1)  ·  Xun Li, M.D.,Ph.D. (1)  ·  Ze-yang Ding (1)

Results publications

PMID 28420720, PMID 40812353, PMID 38870977, PMID 40147791, PMID 40346549

NIH funding

2016 (1), 2017 (1)